P3-136: A Phase II study of XL647 in non-small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations  by Rizvi, Naiyer et al.
Copyright © 2007 by the International Association for the Study of Lung Cancer S737
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
York Oncology Hematology, Latham, NY, USA 7 Ocala Oncology, 
Ocala, FL, USA 8 US Oncology Research, Inc., Ft. Worth, TX, USA 
Background: Nab-paclitaxel has eliminated many of the difﬁculties 
associated with the infusion of standard solvent-based paclitaxel (in 
cremophor). In this phase II, open label trial, patients with advanced 
(stage IIIB or IV) nonsquamous NSCLC received nab-paclitaxel and 
carboplatin in combination with bevacizumab.
Methods: Patients (N=50) enrolled between October 2005 and April 
2006. They received intravenous (IV) nab-paclitaxel 300 mg/m2, 
carboplatin IV AUC=6, and bevacizumab 15 mg/kg on Day 1 of each 
21-day cycle. Patients with CR, PR, or SD received >4 cycles of treat-
ment; however, patients with progression or intolerable toxicity were 
taken off treatment. Response rate, based on RECIST, was the primary 
endpoint.
Results: At baseline, the median age was 67 years; 80% were white 
and 56% were female. Patients received a median of 4 cycles (range, 
<1 - 6). The preliminary response rates are PR 30% and SD 48%; no 
complete responses have been noted. To date, median progression-free 
survival is 7.1 months (range, <1 - 10.6); median survival has not yet 
been reached. Grade 3-4 treatment related toxicities were neutropenia 
(52%); fatigue (19%); neuropathy (15%); thrombocytopenia (10%) 
dyspnea (6%), anorexia, constipation, febrile neutropenia, hemoptysis, 
and nausea and/or vomiting (4% each). 64% of patients are surviving. 
32 patients have come off study prior to 4 cycles due to disease pro-
gression (12%), adverse event (10%), investigator request (8%), sudden 
death (6%), and withdrawal of consent (2%); 16 patients had normal 
study completion (completed 4 cycles of therapy). 
Conclusions: The combination of nab-paclitaxel, carboplatin, and 
bevacizumab is well-tolerated, producing moderate, but manageable, 
neutropenia. This preliminary analysis indicates that the 3-drug combi-
nation has promising activity in ﬁrst-line patients with non-squamous 
NSCLC. 
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Background: XL647 is an orally bioavailable small molecule inhibi-
tor of multiple receptor tyrosine kinases involved in tumorigenesis, 
angiogenesis and metastasis including EGFR/ErbB1, HER2/ErbB2, 
VEGFR2/KDR, and EphB4. In addition, XL647 has preclinical activity 
in the H1975 cell line which harbors the T790M mutation in the EGFR 
gene that confers acquired resistance to erlotinib and geﬁtinib. 
Methods: This is a Simon two-stage study with a primary endpoint of 
efﬁcacy deﬁned as best conﬁrmed response rate. Adult patients (pts) 
with previously untreated advanced NSCLC (Stage IIIB with malig-
nant pleural effusion or Stage IV) with adenocarcinoma histology are 
eligible. Pts must have either an activating mutation of the EGFR gene 
in tumor tissue or meet at least one of the following three demographic 
eligibility criteria: Asian, female (F), minimal (less than 15 pack-years) 
or no smoking history (within the last 25 years). XL647 is administered 
orally as a single dose of 350 mg on days 1-5 of each 14 day cycle. 
Tumor response is assessed every 8 wks by RECIST. The mutational 
status of EGFR gene and other relevant genes in tumor tissue will be 
analyzed for genotypic correlates of response or insensitivity to XL647.
Results: Seventeen pts (12F/5M) with a median age of 62yrs (range 
45-86) have been enrolled to date. Eight pts were never-smokers, 8 had 
<15 pack years (pk-yr) smoking history, and 1 had >15 pk-yr. Four pts 
who have had a partial response (PR) and 1 with stable disease (SD) 
continue on treatment. Six pts have been discontinued due to progres-
sive disease (PD). The remaining 6 pts are too early to evaluate. To date 
EGFR gene mutations were not detected in DNA from the tumors of 4 
pts with PD as well as 1 pt with a PR and 1 pt who had SD, additional 
analysis is ongoing. The most common adverse events reported are 
grade 1 and 2 rash and diarrhea and grade 1 fatigue. A total of 4 SAEs 
have been reported in 3 patients; 1 event of grade 3 pneumonia was 
considered possibly related to study drug, the other 3 SAEs were not 
related.
Conclusions: XL647 appears to have activity and to be well-toler-
ated in a NSCLC patient population enriched for likelihood of having 
an EGFR mutation. Based upon activity seen in stage I, enrolment 
continues in the second stage of the study and updated results including 
mutational analysis of genes in tumor tissue will be presented. 
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Background: SNPs in DNA repair genes may affect response to cyto-
toxic therapy. We investigated SNPs in XPD codons 751 and 312 and 
in RRM1 -37 in 109 stage IIIA (N2) and IIIB NSCLC p treated with 
neoadjuvant chemotherapy and correlated results with event-free (EFS) 
and median (MS) survival. 
Methods: p eligible for surgery received cisplatin day (d) 1, gemcitabi-
ne d 1,8, docetaxel d 1,8,15, every 3 weeks for 3 cycles, followed by 
thoracotomy. DNA was extracted from baseline peripheral lymphocytes 
and genotyping was performed by Taqman. 
Results: Median age, 60 y (range 31-77); 92 males (84%); 45 squa-
mous cell (41%). 4 p (3.9%) attained complete response; 55 (53.9%) 
partial response. 75 p underwent surgery (62 complete, 13 incomplete 
resection); remaining 34 p were unresectable. Median follow-up was 
15.7 months (m) (range, 0.5-74). MS for p still alive is 49.8 m (range, 
6.7-74). MS: 48 m with complete resection, 13 m with incomplete 
resection, 17 m for unresected p. In the univariate analysis of sur-
vival, age <59 y (P=0.03), resection (P<0.001) and XPD312 AspAsp 
(P=0.05) emerged as predictive markers of longer survival. For all 109 
p, those with XPD312 AspAsp had longer EFS and MS than p with Asn 
variants (Table). In addition, for 51 p <59 y, EFS was longer for 24 p 
